Ameriprise Financial Inc. Has $11.91 Million Position in BioTelemetry, Inc. (BEAT)

Ameriprise Financial Inc. increased its stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) by 72.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 356,028 shares of the medical research company’s stock after buying an additional 149,379 shares during the quarter. Ameriprise Financial Inc. owned 1.24% of BioTelemetry worth $11,909,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after buying an additional 626 shares during the period. FNY Partners Fund LP bought a new position in shares of BioTelemetry during the 1st quarter worth approximately $142,000. Dubuque Bank & Trust Co. bought a new position in shares of BioTelemetry during the 2nd quarter worth approximately $142,000. US Bancorp DE bought a new position in shares of BioTelemetry during the 2nd quarter worth approximately $145,000. Finally, State of Alaska Department of Revenue lifted its position in shares of BioTelemetry by 80.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,638 shares of the medical research company’s stock worth $188,000 after buying an additional 2,508 shares during the period. Institutional investors and hedge funds own 77.67% of the company’s stock.

BioTelemetry, Inc. (NASDAQ:BEAT) opened at 33.35 on Tuesday. The firm has a 50-day moving average price of $34.79 and a 200 day moving average price of $32.12. BioTelemetry, Inc. has a 12 month low of $15.25 and a 12 month high of $39.20. The company has a market cap of $1.08 billion, a P/E ratio of 22.38 and a beta of 0.69.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million for the quarter, compared to the consensus estimate of $58.39 million. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. On average, equities analysts expect that BioTelemetry, Inc. will post $0.99 earnings per share for the current year.

WARNING: “Ameriprise Financial Inc. Has $11.91 Million Position in BioTelemetry, Inc. (BEAT)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/10/ameriprise-financial-inc-has-11-91-million-position-in-biotelemetry-inc-beat.html.

Several equities analysts recently commented on the company. Sidoti restated a “buy” rating and set a $49.00 target price (up previously from $42.00) on shares of BioTelemetry in a research report on Thursday, August 10th. BidaskClub upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. Dougherty & Co raised their target price on BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 target price for the company in a research report on Friday, August 11th. Finally, Lake Street Capital restated a “buy” rating and set a $50.00 target price (up previously from $35.00) on shares of BioTelemetry in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average targ

Other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after buying an additional 626 shares during the period. FNY Partners Fund LP bought a new position in shares of BioTelemetry during the 1st quarter worth approximately $142,000. Dubuque Bank & Trust Co. bought a new position in shares of BioTelemetry during the 2nd quarter worth approximately $142,000. US Bancorp DE bought a new position in shares of BioTelemetry during the 2nd quarter worth approximately $145,000. Finally, State of Alaska Department of Revenue lifted its position in shares of BioTelemetry by 80.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,638 shares of the medical research company’s stock worth $188,000 after buying an additional 2,508 shares during the period. Institutional investors and hedge funds own 77.67% of the company’s stock.

BioTelemetry, Inc. (NASDAQ:BEAT) opened at 33.35 on Tuesday. The firm has a 50-day moving average price of $34.79 and a 200 day moving average price of $32.12. BioTelemetry, Inc. has a 12 month low of $15.25 and a 12 month high of $39.20. The company has a market cap of $1.08 billion, a P/E ratio of 22.38 and a beta of 0.69.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million for the quarter, compared to the consensus estimate of $58.39 million. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. On average, equities analysts expect that BioTelemetry, Inc. will post $0.99 earnings per share for the current year.

WARNING: “Ameriprise Financial Inc. Has $11.91 Million Position in BioTelemetry, Inc. (BEAT)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/10/10/ameriprise-financial-inc-has-11-91-million-position-in-biotelemetry-inc-beat.html.

Several equities analysts recently commented on the company. Sidoti restated a “buy” rating and set a $49.00 target price (up previously from $42.00) on shares of BioTelemetry in a research report on Thursday, August 10th. BidaskClub upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. Dougherty & Co raised their target price on BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 target price for the company in a research report on Friday, August 11th. Finally, Lake Street Capital restated a “buy” rating and set a $50.00 target price (up previously from $35.00) on shares of BioTelemetry in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.40.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply